SAN DIEGO, Feb. 8, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the ISI
Annual Conference in New York on
Tuesday, February 15, 2011 at
4:10 p.m. ET / 1:10 p.m. PT. Mark
Foletta, senior vice president, finance and chief financial
officer at Amylin Pharmaceuticals, will provide a corporate
overview.
The presentation will be webcast live through the "Investors"
section of Amylin's corporate website at www.amylin.com, and the
recording will be made available on the website following the
event. To access the live webcast, please log on to Amylin's
website approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information about Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.